Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Lutton

Orthopaedic Surgery Washington, DC Medical Doctor

NPI 1770747230 CMS profile 307041

3 Washington Cir Nw, Suite 404, Washington, DC 20037

Open in the dashboard

General payments

$375,086

659 records reported · program years 2019–2025

Research payments

$450

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$7,834

1 holding reported · through program year 2025

Through program year 2025, David Lutton of Washington, DC is reported in the CMS Open Payments database as having received $375,086 across 659 general payments and $450 in research payments paid to them. They also declared ownership or investment interests valued at $7,834 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142,693 130
2024 General $59,311 132
2024 Research $450 1
2023 General $48,836 105
2022 General $29,726 80
2021 General $32,600 69
2020 General $28,852 47
2019 General $33,067 96
2025 Ownership $7,834 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Lutton
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to David Lutton were reported at $142,693. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year David Lutton Orthopaedic Surgery median Middle half National median
2019 $33,067 $644 $140–$2,844 $163
2020 $28,852 $312 $75–$1,860 $114
2021 $32,600 $520 $117–$2,495 $132
2022 $29,726 $598 $128–$2,731 $149
2023 $48,836 $461 $128–$2,264 $160
2024 $59,311 $497 $134–$2,475 $164
2025 $142,693 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $327,768 473 payments
  2. Avanos Medical $21,667 14 payments
  3. restor3d, inc. $10,780 17 payments
  4. Supreme Orthopedic Systems, LLC $5,408 51 payments
  5. Stryker Corporation $5,127 51 payments
  6. Novartis Pharmaceuticals Corporation $1,938 1 payment
  7. Pinnacle, Inc $928 2 payments
  8. Ferring Pharmaceuticals Inc. $300 14 payments
  9. Zimmer Biomet Holdings, Inc. $253 4 payments
  10. Fidia Pharma USA Inc. $159 7 payments
  11. Other $759 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $192,119 53 payments
  2. Consulting Fee $110,917 79 payments
  3. Travel and Lodging $31,997 153 payments
  4. Honoraria $21,318 4 payments
  5. Food and Beverage $14,256 367 payments
  6. Education $4,480 3 payments
Products named General payments · program years 2019–2025
  1. ON-Q $21,318 4 payments
  2. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $3,041 20 payments
  3. COSENTYX $1,938 1 payment
  4. AEQUALIS PERFORM REVERSED $1,034 8 payments
  5. ARTHROPLASTY IMPLANTS SHOULDER ARTHROPLASTY & FRACTURE REVERS $675 1 payment
  6. ARTHROPLASTY IMPLANTS SHOULDER ARTHROPLASTY & FRACTURE UNIVERS Arthroplasty - Implants - Shoulder Arthroplasty & Fracture - Univers $675 1 payment
  7. ARTHROPLASTY IMPLANTS SHOULDER ARTHROPLASTY & FRACTURE UNIVERS Arthroplasty $420 1 payment
  8. ARTHROPLASTY IMPLANTS REVERS TOTAL SHOULDER REVERS $420 1 payment
  9. ARTHROPLASTY INSTRUMENTS SHOULDER ARTHROPLASTY & FRACTURE VIP TECHNOLOGY $420 1 payment
  10. AEQUALIS ASCEND FLEX $330 2 payments
  11. Other $4,376 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Arthrex, Inc. $450 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

468

Median for Orthopedic Surgery: 203

Drug cost

$2,682

Median for Orthopedic Surgery: $1,433

Branded share of claims

15.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 31 $779
Ondansetron Odt Ondansetron Brand 71 $571
Oxycodone Hcl Generic 72 $338
Meloxicam Generic 94 $292
Amoxicillin Generic 123 $286
Cyclobenzaprine Hcl Generic 26 $135
Gabapentin Generic 14 $119
Tramadol Hcl Generic 26 $102
Methylprednisolone Generic 11 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$248,392

Of which drugs: $11,091

Medicare patients

460

Average age 75

Services billed

3,045

281 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 58%
Osteoporosis 23%
Ischemic heart disease 21%
Cancer 18%
Depression 18%
Diabetes 16%
Chronic kidney disease 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 11 793 $10,829
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 134 337 $252

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $1,938
$1,938 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

660 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record